Preprocedural therapeutic international normalized ratio influence on bleeding complications in atrial fibrillation ablation with continued anticoagulation with warfarin

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 338-344

  Hayashi, Tatsuya ^a   Kumagai, Koji ^b   Naito, Shigeto ^b   Goto, Koji ^b   Kasen, Kenichi ^b   Ohshima, Shigeru ^b   Hachiya, Hitoshi ^a   Hirao, Kenzo ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

Author keywords

Ablation; Atrial fibrillation; Heparin; Warfarin

Indexed keywords

D DIMER; HEPARIN; WARFARIN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CATHETER ABLATION; FALSE ANEURYSM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOMA; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DRUG MONITORING; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTAMINES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 84873826755     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0743     Document Type: Article

References (32)

1. Haïssaguerre M, Marcus FI, Fischer B, Clémenty J. Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation: Report of three cases. J Cardiovasc Electrophysiol 1994; 5: 743-751.
2. Haïssaguerre M, Jaïs P, Shah DC, Gencel L, Pradeau V, Garrigues S, et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-1144.
3. Kumagai K. Catheter ablation of atrial fibrillation: State of the Art. Circ J 2011; 75: 2305-2311.
4. Haïssaguerre M, Jaïs P, Shah DC, Garrigue S, Takahashi A, Lavergne T, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: 1409-1417.
5. Oral H, Scharf C, Chugh A, Hall B, Cheung P, Good E, et al. Catheter ablation for paroxysmal atrial fibrillation: Segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108: 2355-2360.
6. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.
7. Cummings JE, Schweikert RA, Saliba WI, Burkhardt JD, Kilikaslan F, Saad E, et al. Brief communication: Atrial-esophageal fistulas after radiofrequency ablation. Ann Intern Med 2006; 144: 572-574.
8. Onalan O, Lashevsky I, Hamad A, Crystal E. Nonpharmacologic stroke prevention in atrial fibrillation. Cardiovasc Ther 2005; 3: 619-633.
9. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-1886.
10. Sra J, Dhala A, Blanck Z, Deshpande S, Cooley R, Akhtar M. Atrial fibrillation: Epidemiology, mechanisms, and management. Curr Probl Cardiol 2000; 25: 405-524.
11. Swartz JF, Pellersels G, Silvers J, Patten L, Cervantez D. A catheter based curative approach to atrial fibrillation in humans. Circulation 1994; 90(Suppl I): I-335.
12. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
13. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009; 6: 1425-1429.
14. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
15. Hakalahti A, Uusimaa P, Ylitalo K, Raatikainen MJ. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011; 13: 640-645.
16. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22: 248-254.
17. Nakatani Y, Mizumaki K, Nishida K, Hirai T, Sakabe M, Oda Y, et al. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients. Circ J 2012; 76: 317-321.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
19. Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 312-318.
20. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
21. Cannon BC, Kertesz NJ, Friedman RA, Fenrich AL. Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway. J Cardiovasc Electrophysiol 2001; 12: 723-725.
22. Khan IA. Atrial stunning: Basics and clinical considerations. Int J Cardiol 2003; 92: 113-128.
23. O'Shea MJ, Flute PT, Pannell GM. Laboratory control of heparin therapy. J Clin Pathol 1971; 24: 542-546.
24. Freedman JE, Adelman B. Pharmacology of heparin and oral anticoagulants. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. Boston: Blackwell Scientific, 1994; 1155-1171.
25. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012; 76: 2337-2342.
26. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
27. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
28. Latchamsetty R, Gautam S, Bhakta D, Chugh A, John RM, Epstein LM, et al. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 2011; 8: 805-808.
29. Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: A prospective observational study. Cardiovasc Ther 2009; 27: 77-82.
30. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
31. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) Circulation 2004; 110: e82-e292.
32. Inoue H, Nozawa T, Hirai T, Goto S, Origasa H, Shimada K, et al. Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE. Circ J 2010; 74: 650-654.